

# Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

## MC38-OVA

RRID:CVCL\_XJ96

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_XJ96

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_XJ96](https://web.expasy.org/cellosaurus/CVCL_XJ96)

**Proper Citation:** RRID:CVCL\_XJ96

**Description:** Cell line MC38-OVA is a Cancer cell line with a species of origin Mus musculus (Mouse)

**Sex:** Female

**Disease:** Mouse colon adenocarcinoma

**Defining Citation:** [PMID:26453748](#)

**Comments:** Characteristics: Transduced with a OVA-IRES-EGFP construct (PubMed=26453748).

**Category:** Cancer cell line

**Organism:** Mus musculus (Mouse)

**Name:** MC38-OVA

**Cross References:** BioGRID\_ORCS\_Cell\_line:1263, Wikidata:Q95985685

**ID:** CVCL\_XJ96

**Hierarchy:** cvcl\_b288

**Record Creation Time:** 20220427T220749+0000

**Record Last Update:** 20260829T234550+0000

---

### Ratings and Alerts

No rating or validation information has been found for MC38-OVA.

No alerts have been found for MC38-OVA.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Kim Y, et al. (2026) Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells. ACS nano, 20(12), 9925.

Yang Y, et al. (2026) Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8+ T cells. Journal for immunotherapy of cancer, 14(3).

Tripathi C, et al. (2025) Antitumor efficacy of intermittent low-dose erlotinib plus sulindac via MHC upregulation and remodeling of the immune cell niche. International journal of cancer, 157(2), 355.

Ma T, et al. (2025) Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells. Cancer research, 85(19), 3596.

Basavaraja R, et al. (2024) PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies. Cell reports. Medicine, 5(7), 101649.

Gabriely G, et al. (2021) Myeloid cell subsets that express latency-associated peptide promote cancer growth by modulating T cells. iScience, 24(11), 103347.